Estrella Immunopharma held its annual meeting on June 29, 2026, with shareholders voting to ratify the appointment of Macias Gini & O'Connell LLP as its independent accounting firm for the 2026 fiscal year. The vote passed overwhelmingly with over 30.35 million shares in favor and only 400 against.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ESTRELLA IMMUNOPHARMA INC (ESLA)?

Major stakeholders currently include Armistice Capital, LLC ($4.3M), Vanguard Capital Management LLC ($405.4K), Wells Fargo & Company/mn ($280.3K). Based on the latest 13F filings, there are a total of 16 tracked investment funds and institutions maintaining positions in ESLA.

What is the overall institutional sentiment toward ESLA recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $3.9M, driven by 10 managers accumulating shares while 8 reduced their exposure.

Which institutions have been selling or reducing their ESLA positions?

In the latest period, 2 funds trimmed their holdings, and 6 managers completely exited their positions. The aggregate reported sell value was $533.4K.

Are there any notable investors adding ESLA to their portfolios?

Yes, buying activity remains notable. 7 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $5.2M.